Skip to main content
. Author manuscript; available in PMC: 2013 Mar 12.
Published in final edited form as: Ann Surg Oncol. 2012 Jun 6;19(12):3879–3887. doi: 10.1245/s10434-012-2435-y

Figure 2. Panitumumab-IRDye versus aspecific control (IgG-IRDye).

Figure 2

Figure 2

Figure 2

(A) Uptake of the near-infrared (NIR) fluorescence agent panitumumab-IRDye800 versus aspecific IgG-IRDye detected with the Pearl and SPY Systems in mice with flank SCC1 tumors. (B) The tumor-to-background is significantly higher versus the control for both the Pearl and SPY. (C) Panitumumab-IRDye demonstrates significantly greater fluorescence in a tumor versus the split-thickness skin graft for both the Pearl and SPY imager. Error bars indicate the SD.